So what are the chances the FDA panel approves this?
from your assestment , 6000 patients, half of them in Europe. Isis got denied in europe so that leaves 3000 patients for aegr and 1500 patients in US for total 4500 patients.. appr 4500x 300,000= 1.3B. right now aegr trades at 679 million, aegre could double from here. but if FDA denies isis so aegr gets the entire market. aegr will get bought out with this scenrio..